• Revenue up 7 % year-over-year despite volatility in China related to COVID-19 and global supply chain headwinds HOLLISTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31,

Company continues innovating preclinical tools used in new and ongoing small animal research and product development with SmartStudy™ HOLLISTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) has introduced SmartStudy™, an innovative technology feature to its

HOLLISTON, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for first quarter ended March 31, 2022 before the market opens on May 4, 2022, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Revenue up 7% year-over-year as sales momentum continues, despite global supply chain headwinds Gross margin improves to 59% in Q4 driven by strengthening product mix, improved operating leverage HOLLISTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc.

HOLLISTON, Mass., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2021 before the market opens on March 8, 2022, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Strong double digit revenue growth, solid margin performance despite global supply chain disruptions Revenue up 23% year-over-year as sales momentum continues Pre-clinical product revenue up 28% Cellular and Molecular Technologies (CMT) product revenue up 19% HOLLISTON, Mass., Nov.

HOLLISTON, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2021, before the market opens on November 3, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Strong double digit revenue growth, solid margin performance despite global supply chain disruptions Revenue up 25% year-over-year as sales momentum continues Cellular and Molecular (CMT) product revenue up 22% Pre-clinical product revenue up 20% Operating margins impacted by higher global supply

HOLLISTON, Mass., July 19, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2021 before the market opens on August 5, 2021, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Sales effectiveness, pre-clinical product demand and disciplined cost management result in improved revenues and margins Revenue up 14% as sales momentum from Q4’20 continues Pre-clinical product revenue up 24% Operating margin significantly improves year-over-year on GAAP and adjusted basis